Aspirin Use Doesn't Cut Cancer Incidence in Older T2DM Patients

Share this content:
In subgroup analyses, reduced incidence of cancer seen in participants aged younger than 65 years.
In subgroup analyses, reduced incidence of cancer seen in participants aged younger than 65 years.

(HealthDay News) -- For Japanese patients with type 2 diabetes, low-dose aspirin is not associated with reduced cancer incidence, except in those younger than 65 years, according to a study published online in Diabetes Care.

Sadanori Okada, MD, from Nara Medical University in Kashihara, Japan, and colleagues conducted a post-trial follow-up of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial. A total of 2536 patients with type 2 diabetes were randomized to receive aspirin (81 or 100 mg daily) or no aspirin. Participants were followed from the trial end in 2008 until 2015.

The researchers found that 318 cancers occurred during a median follow-up of 10.7 years. There was no significant difference between the aspirin and no-aspirin groups in terms of cancer incidence (hazard ratio, 0.92; 95 % confidence interval, 0.73 to 1.14; P=0.4). Aspirin did not affect cancer incidence in men, women, or those aged ≥65 years in subgroup analyses. There was a decrease in cancer incidence associated with aspirin use among those aged <65 years (hazard ratio, 0.67; 95% confidence interval, 0.44 to 0.99; P=0.048). Aspirin was associated with significantly reduced cancer incidence in participants aged <65 years after adjustment for sex, hemoglobin A1c, smoking status, and administration of metformin and statins (adjusted hazard ratio, 0.66; 95% confidence interval, 0.43 to 0.99; P=0.04).

"Low-dose aspirin did not reduce cancer incidence in Japanese patients with type 2 diabetes," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Reference

Okada S, Morimoto T, Ogawa H, et al. Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial. Diab Care 2018 Jun; dc180368. DOI:10.2337/dc18-0368

You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup